Omeprazole and clopidogrel: Should clinicians be worried?

Jeremiah P. Depta; Deepak L. Bhatt

doi:10.3949/ccjm.77a.09173

Omeprazole and clopidogrel: Should clinicians be worried?

Jeremiah P. Depta, Deepak L. Bhatt

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The US Food and Drug Administration has issued a warning that omeprazole (Prilosec) reduces the antiplatelet activity of clopidogrel (Plavix) by about 50%. However, the warning is based largely on ex vivo data. Preliminary results from a randomized clinical trial revealed no effect on cardiovascular outcomes when omeprazole was given with clopidogrel. We recommend that physicians continue to prescribe a proton pump inhibitor for patients receiving dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have an indication for use of a proton pump inhibitor.

Original language	English
Pages (from-to)	113-116
Number of pages	4
Journal	Cleveland Clinic Journal of Medicine
Volume	77
Issue number	2
DOIs	https://doi.org/10.3949/ccjm.77a.09173
State	Published - Feb 2010
Externally published	Yes

Access to Document

10.3949/ccjm.77a.09173

Cite this

@article{59d3d7fc28c44113a0c750e2a63a2a82,

title = "Omeprazole and clopidogrel: Should clinicians be worried?",

abstract = "The US Food and Drug Administration has issued a warning that omeprazole (Prilosec) reduces the antiplatelet activity of clopidogrel (Plavix) by about 50%. However, the warning is based largely on ex vivo data. Preliminary results from a randomized clinical trial revealed no effect on cardiovascular outcomes when omeprazole was given with clopidogrel. We recommend that physicians continue to prescribe a proton pump inhibitor for patients receiving dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have an indication for use of a proton pump inhibitor.",

author = "Depta, {Jeremiah P.} and Bhatt, {Deepak L.}",

year = "2010",

month = feb,

doi = "10.3949/ccjm.77a.09173",

language = "English",

volume = "77",

pages = "113--116",

journal = "Cleveland Clinic Journal of Medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "2",

}

TY - JOUR

T1 - Omeprazole and clopidogrel

T2 - Should clinicians be worried?

AU - Depta, Jeremiah P.

AU - Bhatt, Deepak L.

PY - 2010/2

Y1 - 2010/2

N2 - The US Food and Drug Administration has issued a warning that omeprazole (Prilosec) reduces the antiplatelet activity of clopidogrel (Plavix) by about 50%. However, the warning is based largely on ex vivo data. Preliminary results from a randomized clinical trial revealed no effect on cardiovascular outcomes when omeprazole was given with clopidogrel. We recommend that physicians continue to prescribe a proton pump inhibitor for patients receiving dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have an indication for use of a proton pump inhibitor.

AB - The US Food and Drug Administration has issued a warning that omeprazole (Prilosec) reduces the antiplatelet activity of clopidogrel (Plavix) by about 50%. However, the warning is based largely on ex vivo data. Preliminary results from a randomized clinical trial revealed no effect on cardiovascular outcomes when omeprazole was given with clopidogrel. We recommend that physicians continue to prescribe a proton pump inhibitor for patients receiving dual antiplatelet therapy who are at risk of gastrointestinal bleeding or have an indication for use of a proton pump inhibitor.

UR - http://www.scopus.com/inward/record.url?scp=77951915589&partnerID=8YFLogxK

U2 - 10.3949/ccjm.77a.09173

DO - 10.3949/ccjm.77a.09173

M3 - Article

C2 - 20124268

AN - SCOPUS:77951915589

SN - 0891-1150

VL - 77

SP - 113

EP - 116

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

IS - 2

ER -

Omeprazole and clopidogrel: Should clinicians be worried?

Abstract

Access to Document

Fingerprint

Cite this